Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05753995 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immuno-Positron Emission Tomography (PET)-Glioma Study, a Proof-of-principle Imaging Study

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 1, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jan 1, 2024 to Mar 1, 2024
    • Study sites: 0 to 1
    v4
  3. Start date: Jul 2023 to Jan 1, 2024v3
  4. Primary endpoint revised
    • Study description expanded, about 22 words
    • Study title expanded, about 3 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Imaging of proinflammatory activated microglia by Purine 2X7 (P2X7) receptor scintigraphy in Positron Emission Tomography (PET) scanner in Glioblastoma patients.
Trial Details
NCT Number NCT05753995
Lead Sponsor Kepler University Hospital
Conditions
(from sponsor)		 Glioblastoma
Related terms Glioblastoma
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov